Scientists have discovered a new way to target cancer through manipulating a master switch responsible for cancer cell growth.
Altered VEGF splicing was reversed by wild-type WT1, knockdown of SRSF1, or SRPK1 and inhibition of SRPK1, which prevented in vitro and in vivo angiogenesis and associated tumor growth.
This example is same.